Matt O'Brien
Stock Analyst at Piper Sandler
(2.29)
# 2,517
Out of 4,840 analysts
178
Total ratings
44.59%
Success rate
-5.28%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TMDX TransMedics Group | Reiterates: Overweight | $105 → $125 | $128.53 | -2.75% | 11 | May 9, 2025 | |
| GMED Globus Medical | Maintains: Overweight | $100 → $80 | $59.59 | +34.25% | 12 | May 9, 2025 | |
| CVRX CVRx, Inc. | Maintains: Overweight | $20 → $12 | $6.96 | +72.41% | 9 | May 9, 2025 | |
| KIDS OrthoPediatrics | Maintains: Overweight | $40 → $30 | $21.16 | +41.78% | 2 | May 8, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $90 | $85.33 | +5.47% | 11 | May 2, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $13 → $15 | $12.32 | +21.75% | 3 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Overweight | $36 → $30 | $21.48 | +39.66% | 8 | May 1, 2025 | |
| GKOS Glaukos | Maintains: Overweight | $180 → $165 | $96.97 | +70.16% | 10 | Apr 15, 2025 | |
| KMTS Kestra Medical Technologies | Initiates: Overweight | $27 | $22.64 | +19.28% | 1 | Mar 31, 2025 | |
| TELA TELA Bio | Downgrades: Neutral | $5 → $2 | $1.48 | +35.14% | 6 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $3.43 | +2.04% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $122.96 | +13.86% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $14.95 | +73.91% | 1 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $326.64 | -5.09% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $272.63 | +21.04% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $33.99 | +47.10% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $18.92 | -15.43% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $106.17 | +8.32% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $6.07 | +97.69% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $383.78 | +9.44% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $125 → $140 | $121.63 | +15.10% | 2 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $75 | $58.53 | +28.14% | 3 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $81.18 | +10.86% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $80 | $57.78 | +38.46% | 12 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $18.55 | +34.77% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $2.48 | +20.97% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $1.76 | +155.68% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $94.21 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $2.82 | +431.91% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $80.59 | +34.94% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $18 | $2.59 | +601.93% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $30.87 | +159.15% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $2.89 | +315.22% | 1 | Jun 24, 2020 |
TransMedics Group
May 9, 2025
Reiterates: Overweight
Price Target: $105 → $125
Current: $128.53
Upside: -2.75%
Globus Medical
May 9, 2025
Maintains: Overweight
Price Target: $100 → $80
Current: $59.59
Upside: +34.25%
CVRx, Inc.
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $6.96
Upside: +72.41%
OrthoPediatrics
May 8, 2025
Maintains: Overweight
Price Target: $40 → $30
Current: $21.16
Upside: +41.78%
DexCom
May 2, 2025
Maintains: Overweight
Price Target: $100 → $90
Current: $85.33
Upside: +5.47%
Alphatec Holdings
May 2, 2025
Reiterates: Overweight
Price Target: $13 → $15
Current: $12.32
Upside: +21.75%
Tandem Diabetes Care
May 1, 2025
Maintains: Overweight
Price Target: $36 → $30
Current: $21.48
Upside: +39.66%
Glaukos
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $96.97
Upside: +70.16%
Kestra Medical Technologies
Mar 31, 2025
Initiates: Overweight
Price Target: $27
Current: $22.64
Upside: +19.28%
TELA Bio
Mar 21, 2025
Downgrades: Neutral
Price Target: $5 → $2
Current: $1.48
Upside: +35.14%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $3.43
Upside: +2.04%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $122.96
Upside: +13.86%
Feb 24, 2025
Initiates: Overweight
Price Target: $26
Current: $14.95
Upside: +73.91%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $326.64
Upside: -5.09%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $272.63
Upside: +21.04%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $33.99
Upside: +47.10%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $18.92
Upside: -15.43%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $106.17
Upside: +8.32%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $6.07
Upside: +97.69%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $383.78
Upside: +9.44%
Oct 25, 2024
Reiterates: Overweight
Price Target: $125 → $140
Current: $121.63
Upside: +15.10%
Oct 8, 2024
Reiterates: Overweight
Price Target: $75
Current: $58.53
Upside: +28.14%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $81.18
Upside: +10.86%
Aug 1, 2024
Maintains: Overweight
Price Target: $95 → $80
Current: $57.78
Upside: +38.46%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $18.55
Upside: +34.77%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $2.48
Upside: +20.97%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $1.76
Upside: +155.68%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $94.21
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $2.82
Upside: +431.91%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $80.59
Upside: +34.94%
Jan 29, 2021
Downgrades: Neutral
Price Target: $25 → $18
Current: $2.59
Upside: +601.93%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $30.87
Upside: +159.15%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $2.89
Upside: +315.22%